Eikon Therapeutics, Inc. (NASDAQ:EIKN) Stock Has Average Target Price of $25.00 According to Brokerages

Shares of Eikon Therapeutics, Inc. (NASDAQ:EIKN) have received an average recommendation of “Moderate Buy” from the nine brokerages that are covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation, five have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $24.67.

A number of research firms have recently weighed in on EIKN. Wedbush lowered their price target on shares of Eikon Therapeutics from $5.00 to $4.00 and set an “underperform” rating on the stock in a report on Friday, August 14th. Cantor Fitzgerald reissued an “overweight” rating on shares of Eikon Therapeutics in a research report on Friday, August 21st. Weiss Ratings raised Eikon Therapeutics from a “sell (e-)” rating to a “sell (e)” rating in a report on Monday, August 3rd. HC Wainwright assumed coverage on shares of Eikon Therapeutics in a report on Friday. They set a “buy” rating and a $23.00 price objective on the stock. Finally, Mizuho upgraded shares of Eikon Therapeutics to a “strong-buy” rating in a research note on Wednesday, September 16th.

Eikon Therapeutics Stock Up 3.8%

Eikon Therapeutics stock opened at $7.70 on Tuesday. Eikon Therapeutics has a fifty-two week low of $6.45 and a fifty-two week high of $17.40. The company has a 50 day moving average price of $9.37 and a 200-day moving average price of $9.91.

Eikon Therapeutics (NASDAQ:EIKN) last released its quarterly earnings data on Thursday, August 13th. The company reported ($1.63) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.61) by ($0.02). As a group, analysts predict that Eikon Therapeutics will post -7.24 earnings per share for the current year.

Insider Buying and Selling

In other Eikon Therapeutics news, major shareholder Group Iv Gp Lp Column bought 89,200 shares of Eikon Therapeutics stock in a transaction that occurred on Thursday, September 3rd. The stock was purchased at an average price of $11.56 per share, with a total value of $1,031,152.00. Following the completion of the acquisition, the insider directly owned 89,200 shares in the company, valued at approximately $1,031,152. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Institutional Investors Weigh In On Eikon Therapeutics

Hedge funds have recently modified their holdings of the company. BlackRock Inc. grew its holdings in Eikon Therapeutics by 29.0% in the 2nd quarter. BlackRock Inc. now owns 4,281,425 shares of the company’s stock valued at $55,873,000 after buying an additional 962,046 shares in the last quarter. State Street Corp acquired a new stake in shares of Eikon Therapeutics in the second quarter valued at $4,621,000. Parkman Healthcare Partners LLC acquired a new position in shares of Eikon Therapeutics during the second quarter worth about $3,341,000. Comprehensive Financial Management LLC purchased a new position in Eikon Therapeutics in the second quarter worth approximately $1,517,000. Finally, Bank of New York Mellon Corp acquired a new position in Eikon Therapeutics during the 2nd quarter worth approximately $624,000.

Eikon Therapeutics Company Profile

Eikon Therapeutics is a biotechnology company focused on discovering and developing medicines using advanced single-molecule imaging, cell biology and computational technologies. Its platform is designed to track the behavior of proteins and other molecular targets in living cells, with the goal of improving the understanding of disease biology and identifying potential drug candidates.

The company is developing a pipeline of therapeutics, including investigational treatments in areas such as oncology and other serious diseases.